N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis

@inproceedings{Conus2018NacetylcysteineI,
  title={
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis},
  author={Philippe Conus and Larry J. Seidman and Margot Fournier and Lijing Xin and Martine Cleusix and Philipp S. Baumann and Carina Ferrari and A. D. Cousins and Luis Enrique Mu{\~n}oz Alameda and Mehdi Gholam-Rezaee and Philippe Golay and Raoul Jenni and T -U Wilson Woo and Matcheri S. Keshavan and Chin B. Eap and Joanne D Wojcik and Michel Cu{\'e}nod and Thierry Buclin and Rolf Gruetter and Kim Q Do},
  booktitle={Schizophrenia bulletin},
  year={2018}
}
Biomarker-guided treatments are needed in psychiatry, and previous data suggest oxidative stress may be a target in schizophrenia. A previous add-on trial with the antioxidant N-acetylcysteine (NAC) led to negative symptom reductions in chronic patients. We aim to study NAC's impact on symptoms and neurocognition in early psychosis (EP) and to explore whether glutathione (GSH)/redox markers could represent valid biomarkers to guide treatment. In a double-blind, randomized, placebo-controlled… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Similar Papers

Loading similar papers…